medigraphic.com
ISSN 2448-8909 (Print)

2009, Number 1

<< Back Next >>

Med Crit 2009; 23 (1)

Glycemia as a predictor of morbi-mortality in critical ill patients

Chávez-Pérez JP, Sánchez-Velázquez LD

Language: Spanish
References: 32
Page: 25-30
PDF size: 70.22 Kb.


ABSTRACT

Introduction: It has been possible to reduce morbi-mortality rates in critically ill patients by a strict control of glycemia.
Objective: To determine the importance of glycemia as a predictor of morbi-mortality in Intensive Care Units in Mexico City.
Design: Study of a prospective cohort in twelve Intensive Care Units in Mexico City.
Subjects: 3,821 patients were included.
Method: Demographic and clinical variables as well as glycemia levels in the first 20 days of stay in ICUs were collected. Then differences in glycemia levels between survivors and nonsurvivors were established. Next, regressions for glycemia thresholds of ‹ 110, ‹ 125, ‹ 150, ‹ 175, ‹ 200 mg/dL were made. Finally, the relationship between glycemia and co-morbidity (acquired in ICUs) and mortality was established. The statistical analysis was multivariate and was considered significant at p ‹ 0.05.
Results: The regressions were statistically significant for all the glycemia thresholds investigated (‹ 110, ‹ 125, ‹ 150, ‹ 175, ‹ 200 mg/dL), (at a p ‹ .001 for all the thresholds).
Conclusions: Surviving patients had lower glycemia levels than non-surviving patients. In Mexican severely ill patients the average thresholds of daily glycemia ‹ 150 mg/dL, seems to lower the risk of morbi-mortality, although as some other prognostic assessment confirm, the glycemia level is not a good predictor of morbi-mortality at ICUs.


REFERENCES

  1. Mizock BA. Metabolic derangements in sepsis and septic shock. Crit Care Clin 2000;16:16-30.

  2. Stoner HB. Metabolism after trauma an in sepsis. Circ Shock 1986;19:75-87.

  3. Wilmore DW. The wound as an organ. In: Little RA, Frayn KN, eds. The Scientific basis for the care on the critically III. Manchester, UK: Manchester University Press; 1986:98:45-59.

  4. Mizock BA. Alterations in carbohydrate metabolism during stress: A review of literature. Am J Med 1995;98:75-84.

  5. Rivier C, Chizzonite R, Cale W. In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated trough interleukin-1. Endocrinology 1989;125:2800 Abstract.

  6. Dunn AJ. The role of interleukin-1 and tumor necrosis factor alpha in the neurochemical and neuroendocrine responses to endotoxin. Brain Res Bull 1992;29:807 Abstract.

  7. Van den Berghe G, Wouters P, Weekers F, Verwaest Ch, Bruyninckx F, Schetz M et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.

  8. Van den Berghe G, Wouters P, Bouillon R, Weekers F, Verwaest Ch, Schetz M et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003;31:359-66.

  9. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters P, Milants I, Van Wijngaerden et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.

  10. Anname D, Melchior JC. Hormone replacement therapy for the critically ill. Crit Care Med 2003;31:634-5.

  11. Sonksen P, Sonkesen J. Insulin: understanding its action in health and disease. Br J Anaesth 2000;85:69-79.

  12. Levovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;2 Suppl:S135-S148.

  13. Finney SJ, Zekveld C, Elia A, Ebans TW. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041-7.

  14. Saltiel AR, Kahn R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.

  15. Modlin R, Brigthbill H. The toll of innate immunity on microbials pathogens. N Engl J Med 1999;340:1834-5.

  16. Voll RE, Hermann M, Roth EA, Stach C, Kalden JR. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.

  17. Hotchkiss R, Karl I. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.

  18. Russell J. Management of sepsis. N Engl J Med 2006;355:

  19. 1699-1713.

  20. Rassias AJ, Marrin CA, Arruda J, Whalen P, Beach M, Yeager M. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999;88:1011-16.

  21. Gallacher SJ, Thompson G, Fraser WD. Neutrophil bactericidal function in diabetes mellitus: Evidence for association with blood glucose control. Diabetes Med 1995;12:916-20.

  22. Dandona P, Aljada A, Mohanty P. Insulin Inhibits Intranuclear Nuclear Factork B and stimulates 1k B in Mononuclear Cells in Obese Subjects: Evidence for an anti-inflammatory effect ? J Clin Endocrinol Metab 2001;86:3257-65.

  23. Barnes PJ, Karin M. Nuclear factor B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.

  24. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001;86:3266-70.

  25. Siroen MP et al. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: A possible explanation of reduced morbidity and mortality. Crit Care Med 2005;33:504-10.

  26. Castillo L, Al-Khadra E. Hyperglycemia, asymmetric dimethylarginine, and patient survival: Dysregulation of complex networks and the metabolic basis of disease. Crit Care Med 2005;33:674-6.

  27. Dayoub H, Achan V, Adimoolam S. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Genetic and physiological evidence. Circulation 2003; 108:3042-7.

  28. Stuhlinger M, Abbasi F, Chu J. Relationship between insulin resistance and endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.

  29. Ito A, Tsao P, Adimmolam, Kimoto M, Ogawa T, Cooke J. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-5.

  30. Williams S, Cusco J, Roddy M, Johnstone M, Creager M. Impaired nitric oxide-mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74.

  31. Dellinger R. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.

  32. Angus D, Linde-Zwirble W, Lidicker J, Clermont G, Carcillo J, Pinsky M. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.




2020     |     www.medigraphic.com